We would love to hear your thoughts about our site and services, please take our survey here.
Trade 200, 'I need shares but don't take price down'. Interesting.
Morning all. Price drifting on no significant news as usual for Aim. Next announcement likely to include CEO appointment and news on integration of Texrad lung into NHS and Europe. Feedbackers have learnt to be patient and deal with these periods of drift!
Morning El, Alan Green seems to share our thoughts on future CEO, Simon Sturge with his background would appear to be a great fit. We shall wait and see...
Evening all. I am really pleasantly surprised to see the price hold up since David Crabb departure, not what I expected at all. The positive reaction to the arrival of 'golden boy' was seen in some quarters as heralding great progress, now it seems his departure has brought about a similar reaction! You couldn't write it but hey this is AIM after all. Looking carefully to see next appointment of CEO, medical or pharmaceutical?
Hi Shaz, tried to buy £800, no chance! Never known that before for such a small quantity.
Lasted less than 6 months. I wonder why? Need decent replacement asap.
As you were clever enough to find the link (in the public domain?), is it worth a brief email to Lara in investor relations?
I see Teathers are taking part in offering placing at 2.5p. This seems unlikely to attract investors when I can buy open market at 2.1p. BOD have handled this poorly imho.
Caterham my mistake, yes it's main market. I am invested in FDBK as well, which owns the Texrad product and is licenced to FBDU. FDBK is AIM.
'FDA clearance is expected by Q2'. In comparison with this statement it's late and AIM markets judges uncertainty severely.
Was expected quarter 2, perhaps delay is unsettling some investors?
Afternoon mate! I thought such games were confined to CTAG and UKOG boards. Would rather go for market capitalization figure than sp as don't know how many shares will be in issue!! CE lung in NHS and Europe clinical settings later this year, as announced earlier by board, will be immense as it will validate the technology in radiologists and oncologists minds. Once validated lots more will follow imo. I expect a minimum mcap of 30 million. DYOR.
Hi El, thanks for the link. He quotes CEO again ' no imminent placing'. If he's wrong.....
Another delayed buy from Friday cropped up 600,000 @ 1.85, wonder if others directors been opening their wallets.
Quite excited about this week after NED share purchases and looking forward to some positive news.
Recovering from incredible heat in Norfolk this week, grass already brown and no wet stuff in sight. Canaries been back for pre season training, received £35million in transfer fees spent 10/6d, it'll end in tears down at the carra I'm afraid. Hope QPR pre season preps more hopeful. All the best.
That is truly brilliant news and continues to see the new board align themselves with us long term shareholders. Great news to end the week. Enjoy weekend everyone.
Hi El! Significant number of large trades last few days, any thoughts on buys v sells? Buyers not deterred by spread which is largest for some months.
Morning all. Long term expectations of a buy out by a mammoth (TC) shareholder will reap extraordinary returns for the board and long term shareholders.
You been on the wacky baccy my friend?
Totally unrelated but a nice touch from Thor Mining issuing an RNS this afternoon to shareholders who may be concerned about decline in market capitalization. Designed to reassure and demonstrate transparency to shareholders. Am not in but Mick Billings obviously has shareholders high on his list. Wish more companies would do same!!
Morning chaz. Markets love contracts with revenues, milestones being hit and transparency about expectations. Lots of money raised in last year, £1.2million and supported by long term holders other than resigned director Trevor Brown. Lack of news on clinical adoption on Texrad lung, apparent secrecy about progress with JV 's announced in last two years and no idea on revenue expectations. Market will judge accordingly. Lots of hard work going on by New board I'm told but until anything is over the line price will drift. The equity raises in last year with no formal announcements 're progress on how money used (sales and marketing and product development) just encourages market to view negatively. New board need to deliver in 2018.
Texrad lung in clinical setting -"large scale commercial roll out"."By the end of 2018 early adopters using Texrad lung in UK AND Europe. Game changing and transformational for Feedback, recent Board appointments suggest preparation taking place. GLA.